Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRMT5 | O14744 | 2/20 | 0.47 |
| ▸ | EGFR | P00533 | 9/20 | 0.41 |
| ▸ | ERBB2 | P04626 | 8/20 | 0.41 |
| ▸ | IGF1R | P08069 | 1/20 | 0.40 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4668434 | 0.93 | EGFR (0.51) | PRMT5EGFRERBB2IGF1R | |
| SCHEMBL4668432 | 0.93 | EGFR (0.51) | PRMT5EGFRERBB2IGF1R | |
| SCHEMBL4133629 | 0.91 | PRMT5 (0.44) | PRMT5EGFRERBB2IGF1RALOX5 | |
| SCHEMBL4133627 | 0.91 | PRMT5 (0.44) | PRMT5EGFRERBB2IGF1RALOX5 | |
| SCHEMBL4122891 | 0.85 | EGFR (0.50) | PRMT5EGFRERBB2ALOX5 | |
| SCHEMBL4122888 | 0.85 | EGFR (0.50) | PRMT5EGFRERBB2ALOX5 | |
| SCHEMBL4635258 | 0.78 | EGFR (0.48) | EGFRERBB2ALOX5 | |
| SCHEMBL4635253 | 0.77 | EGFR (0.48) | EGFRERBB2ALOX5 | |
| SCHEMBL4635255 | 0.77 | EGFR (0.48) | EGFRERBB2ALOX5 | |
| SCHEMBL4122898 | 0.77 | MAPT (0.49) | EGFRERBB2ALOX5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090088432-A1 | Thiazolinones and Oxazolinones and their Use as Ptp1b Inhibitors | TORRENT PHARMACEUTICALS LIMITED (IN) | 2009-04-02 | — | — | US | claimed |
| US-20090088432-A1 | Thiazolinones and Oxazolinones and their Use as Ptp1b Inhibitors | TORRENT PHARMACEUTICALS LIMITED (IN) | 2009-04-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090088432-A1 | Thiazolinones and Oxazolinones and their Use as Ptp1b Inhibitors | PTPRF, PTPA, PTPRJ | PRMT5 2528/4885EGFR 729/4885ERBB2 138/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.